Phase 1 evaluation of APN401, an autologous CBL-B-silenced PBMC therapy, in advanced solid tumors
Authors:
- Alexander DohnalADAlexander Dohnal
- Nina WorelNWNina Worel
- Thomas BogenriederTBThomas Bogenrieder
- Thorsten FuerederTFThorsten Fuereder
- Martin BurianMBMartin Burian
- Dominik WolfDWDominik Wolf
- Gerald PragerGPGerald Prager
- Richard GreilRGRichard Greil
- Anja Peterbauer-ScherbAPAnja Peterbauer-Scherb
- Beate SchrenkBSBeate Schrenk
- Stefan BunkaSBStefan Bunka
- Ernesto AbilaEAErnesto Abila
Open Access
- 5 October 2026
- journal article
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (4)
Abstract
No abstract availableFunding Information
- Österreichische Forschungsförderungsgesellschaft
This publication has 30 references indexed in Scilit:
- Accelerating and optimising CAR T-cell manufacture to deliver better patient productsThe Lancet Haematology, 2024
- LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulationImmunity, 2024
- Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapyCancer Letters, 2020
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challengesNature Reviews Drug Discovery, 2020
- Regulation of immune responses by E3 ubiquitin ligase Cbl-bCellular Immunology, 2019
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsThe Lancet Oncology, 2017
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor MicroenvironmentTrends in Immunology, 2016
- Perforin and granzymes: function, dysfunction and human pathologyNature Reviews Immunology, 2015
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-bNature, 2000